Expert Opinion on Biological Therapy

Article	Citations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	122
Biosimilars and access to biologic therapy in immune-mediated diseases	63
Antibody drug conjugates for glioblastoma: current progress towards clinical use	61
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions	56
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	53
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	53
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	42
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	39
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	38
The endosomal-lysosomal system in ADC design and cancer therapy	38
Aflibercept biosimilars – so near, yet so far	33
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	30
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	27
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	27
Signaling new therapeutic opportunities: cytokines in prostate cancer	27
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	27
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	25
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	25
Correction	24
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	24
Long-acting delivery and therapies for neovascular age-related macular degeneration	23
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas	22
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	22
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	22
Correction	21

Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	21
Unmet needs in cervical cancer – can biological therapies plug the gap?	20
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	20
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	20
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	20
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	20
Correction	19
An evaluation of guselkumab for the treatment of ulcerative colitis	19
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis	19
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies	19
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	18
Strategies for extending the half-life of biotherapeutics: successes and complications	18
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	18
Cell population data as predictive biomarkers for biologic therapy response in psoriasis	18
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	18
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	18
Dynamics of biological markets with multiple biosimilar competitors in the United States	18
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	17
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	16
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	16
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	16
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	16
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	16
The nail in psoriatic arthritis: new insights into prognosis and treatment	15
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	15
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	15
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	15
Where do we stand with radioimmunotherapy for acute myeloid leukemia?	15
Management of proctitis in ulcerative colitis and the place of biological therapies	15
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	14
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	14
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	14
Recent advances in delivering RNA-based therapeutics to mitochondria	14
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	13
Emerging peptide-based technology for biofilm control	13
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease	13
An evaluation of pozelimab for the treatment of CHAPLE disease	13
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	13
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	13
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	13
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	13
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	13
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	13
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	13
Biological agents targeting interleukin-13 for atopic dermatitis	13
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	13
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence	13
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients	12
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	12
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	12

Treating psoriasis in the elderly: biologics and small molecules	12
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	12
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	12
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	12
Tarlatamab for small-cell lung cancer	12
Belimumab patient profile in Spain: evolution during the last decade and future directions	12
Tremelimumab for the treatment of hepatocellular carcinoma	12
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	11
Correction	11
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	11
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	11
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence	11
Recent developments and future clinical prospects of polyclonal antibody therapies	11
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	11
Biosimilars in osteoporosis treatment: focus on denosumab	11
Non-traditional approaches for control of antibiotic resistance	11
Antibody therapeutics for epithelial ovarian cancer	11
Clinical management and innovation in fracture non-union	11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects	11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	10
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	10
Epcoritamab in B-cell malignancies: current status and prospects	10
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	10
Sargramostim in acute radiation syndrome	10
X-linked myotubular myopathy: an untreated treatable disease	10
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	10
Prostate cancer immunotherapy	10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	10
Biologics in rectal cancer	9
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics	9
Current status and future potential of CD123-based targeted therapies for acute leukemia	9
Expression of Concern:	9
Rilonacept for the treatment of recurrent pericarditis	9
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	9
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	9
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	9
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	9
Hemophilia A gene therapy: current and next-generation approaches	9
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	9
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	9
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	9
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	9
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	9
Ravulizumab for the treatment of myasthenia gravis	9
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	8
CAR T cells for solid tumors – developments to watch in 2023	8
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	8
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	8
The future of cellular therapy for the treatment of renal cell carcinoma	8
Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey	8
The future of interleukin gene therapy in head and neck cancers	8
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	8
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	8
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	8
Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies	7
An evaluation of rozanolixizumab-noli for the treatment of anti-AChR and anti-MuSK antibody-positive generalized myasthenia gravis	7
Belantamab mafodotin in multiple myeloma	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
The future of aptamers in cancer diagnosis, prognosis and treatment	7
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder	7
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence	7
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	7
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars	7
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations	7
The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?	7
Non-TNF biologics and their biosimilars in rheumatoid arthritis	7
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension?	7
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	7
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis	7
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting	6
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm	6
Treatment options for advanced hepatocellular carcinoma: the potential of biologics	6
The future of cancer vaccines against colorectal cancer	6
Literature review and expert opinion on diagnosis and current management of generalized pustular psoriasis	6
An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas	6
Perceptions of airway gene therapy for cystic fibrosis	6

Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives	6
Gene therapy for choroideremia: progress, potential and pitfalls	6
Real-world effectiveness and predictors of complete skin clearance (PASI 100) with anti-IL-23 monoclonal antibodies in moderate-to-severe psoriasis: a retrospective cohort study	6
Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?	6
Immune checkpoint inhibitors for the treatment of melanoma	6
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?	6
Correction	6
Current and preclinical treatment options for Merkel cell carcinoma	6
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel	6
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma	6
Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast	6
Improving health literacy and patient-directed knowledge of fecal microbiota transplantation (FMT) through analysis of readability: a cross-sectional infodemiology study	6
Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis	6
Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery	6
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial	6
Could siRNA therapeutics change the way we treat dyslipidemia?	6
Hypoxic storage of red blood cells to improve transfusion outcomes in hematological malignancies	6
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges	5
Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?	5
Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience	5
How treatment choices influence the onset and outcomes of uveitis in juvenile idiopathic arthritis: a retrospective cohort study	5
Biologics for dengue prevention: up-to-date	5
Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey	5
Emerging role of monoclonal antibodies in the treatment of IgA nephropathy	5
Nivolumab + relatlimab for the treatment of unresectable or metastatic melanoma	5
Pathogenesis-oriented therapy of psoriasis using biologics	5
Use of rilonacept in patients with recurrent pericarditis during COVID-19 disease	5
Bintrafusp alfa and its unsuccessful development journey towards cervical cancer treatment	5
Recent developments in CD19-targeted therapies for follicular lymphoma	5
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center	5
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer	5
Elotuzumab in multiple myeloma	5
Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome	5
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients	5
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma	5
Oncolytic virus therapy for malignant gliomas: entering the new era	5
An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer	5
Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?	5
Therapeutic monoclonal antibodies for COVID-19 management: an update	5
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach	5
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis	5
An evaluation of nipocalimab for the treatment of generalized myasthenia gravis	4
Sarilumab in the treatment of rheumatoid arthritis: future perspectives	4
Addressing practical challenges with bispecific antibody therapy in multiple myeloma	4
T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement	4
Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors	4
Correction	4
Clinical advances in biological therapy for generalized pustular psoriasis: a review	4
Optimizing the use of vilobelimab for the treatment of COVID-19	4
A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence	4
ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?	4
Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics	4
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects	4
Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chron	4
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?	4
Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment	4
Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development	4
Short and long-term economic implications of biosimilars	4
Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review	4
Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis	4
Emerging anti-spike monoclonal antibodies against SARS-CoV-2	4
Perispinal etanercept stroke trial design: PESTO and beyond	4
The evolving therapeutic landscape of diabetic retinopathy	4
Targeting cervical cancer with anti-PD-1 antibodies: what is new?	4
Challenges and opportunities when transitioning from in vivo gene replacement to in vivo CRISPR/Cas9 therapies – a spotlight on hemophilia	4
Transitioning immunotherapy in neuromyelitis optica spectrum disorder – when and how to switch	4
Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities	4
Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance	4
Monoclonal antibodies as adjuvant therapies for resected melanoma	3
Biological therapies for myasthenia gravis	3
Mosunetuzumab for the treatment of follicular lymphoma	3
Switching CGRP(r) MoAbs in migraine: what evidence?	3
Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease	3
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents	3
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy	3
Biologics for psoriasis: is there any unmet need left?	3
Corticosteroids, hyaluronic acid, platelet-rich plasma, and cell-based therapies for knee osteoarthritis - literature trends are shifting in the injectable treatments’ evidence: a systematic review an	3
The cell replacement therapeutic potential of human pluripotent stem cells	3
Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use	3
Reframing guselkumab’s benefit in ulcerative colitis: insights from QUASAR and emerging evidence	3
Management of metastatic melanoma with combinations including PD-1 inhibitors	3
Developing combination therapies with biologics in triple-negative breast cancer	3
Clinical use of biologics in juvenile idiopathic arthritis: lessons learned from real-world studies	3
Recent advances in stem cell therapy for erectile dysfunction: a narrative review	3
What role can LAG-3-blocking antibodies play in melanoma therapy?	3
Efficacy and safety of the ustekinumab biosimilar, Bmab 1200, versus reference ustekinumab in moderate-to-severe plaque psoriasis: 28‑week results of the randomized, double-blind, Phase 3 STELLAR-2 st	3
Small molecule-regulated switches to provide functional control of CAR T cells within the patient	3
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healt	3
Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity	3
Adjuvant immunotherapy for locally advanced renal cell carcinoma	3
Biological therapy in elderly patients with acute myeloid leukemia	3
Antibody-based therapeutics for chronic rhinosinusitis with nasal polyps	3
What is ‘ chronic ’ pustular psoriasis? Identifying candidates for long-term subcutaneous spesolimab treatment	3
Biologic insights from single-cell studies of psoriasis and psoriatic arthritis	3
A plain language summary of the pooled safety results of adalimumab-adbm from the VOLTAIRE clinical trials in people with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	3